Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Archive

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Heparin-induced thrombocytopenia in 2017 and beyond

DOI: https://doi.org/10.1160/TH16-05-0403
Issue: 2016: 116/5 (Nov) pp. 777-1002
Pages: 975-986
Ahead of Print: 2016-08-19

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

A propensity score matched analysis

Online Supplementary Material

G. Y. H. Lip (1, 2), A. Keshishian (3), S. Kamble (4), X. Pan (4), J. Mardekian (5), R. Horblyuk (5), M. Hamilton (4)

(1) University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; (2) Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; (3) STATinMED Research, Ann Arbor, Michigan, USA; (4) Bristol-Myers Squibb Company, Princeton, New Jersey, USA; (5) Pfizer, Inc., New York, New York, USA

Keywords

warfarin, rivaroxaban, major bleeding, dabigatran, Apixaban, non-valvular atrial fibrillation

Summary

In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited data on the comparative risks of major bleeding among newly anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when used in ‘real world’ clinical practice. The study used the Truven MarketScan® Commercial & Medicare supplemental US claims database. NVAF patients aged ≥18 years newly prescribed an oral anticoagulant 01JAN2013–31DEC2014, with a ≥1-year baseline period, were included (study period: 01JAN2012–31DEC2014). Major bleeding was defined as bleeding requiring hospitalisation. Propensity score matching (PSM) was used to balance age, sex, region, baseline comorbidities, and comedications. Cox proportional hazards models were used to estimate the PSM hazard ratio (HR) of major bleeding. Among 45,361 newly anticoagulated NVAF patients, 15,461 (34.1 %) initiated warfarin, 7,438 (16.4 %) initiated apixaban, 17,801 (39.2 %) initiated rivaroxaban, and 4,661 (10.3 %) initiated dabigatran. Compared to matched warfarin initiators, apixaban (HR: 0.53; 95 % CI: 0.39–0.71) and dabigatran (HR: 0.69; 95 % CI: 0.50–0.96) initiators had a significantly lower risk of major bleeding. Patients initiating rivaroxaban (HR: 0.98; 95 % CI: 0.83–1.17) had a non-significant difference in major bleeding risk compared to matched warfarin patients. When comparisons were made between NOACs, matched rivaroxaban patients had a significantly higher risk of major bleeding (HR: 1.82; 95 % CI: 1.36–2.43) compared to apixaban patients. The differences for apixaban-dabigatran and dabigatran-rivaroxaban matched cohorts were not statistically significant. Among newly anticoagulated NVAF patients in the real-world setting, apixaban and dabigatran initiation was associated with significantly lower risk of major bleeding compared to warfarin initiation. When compared to apixaban, rivaroxaban initiation was associated with significantly higher risk of major bleeding.

You may also be interested in...

1.
A propensity-matched analysis of 76,940 patients

Online Supplementary Material

X. Li (1), S. Deitelzweig (2), A. Keshishian (3), M. Hamilton (1), R. Horblyuk (4), K. Gupta (1), X. Luo (5), J. Mardekian (4), K. Friend (1), A. Nadkarni (1), X. Pan (6), G. Y. H. Lip (7, 8)

Thromb Haemost 2017 117 6: 1072-1082

https://doi.org/10.1160/TH17-01-0068

2.
Perioperative “switching”, drug interactions and persistence

J. Koscielny (1), Ch. Rosenthal (2), C. von Heymann (3)

Hämostaseologie 2017 37 4: 267-275

https://doi.org/10.5482/HAMO-16-10-0041

3.

R. C. Gosselin (1), J. Douxfils (2), D. Adcock (3)

Hämostaseologie 2017 37 4: 295-301

https://doi.org/10.5482/HAMO-17-01-0002